Search results
The latest drug shortage: Albuterol. Here's why the medical community is 'super concerned'
USA TODAY via Yahoo News· 1 year agoShortages of the drug albuterol, used to treat asthma and other respiratory illnesses, are expected...
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Motley Fool· 2 years agoRegeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ:...
Why Inovio Pharmaceuticals' Shares Jumped on Thursday
Motley Fool· 1 year agoShares of Inovio Pharmaceuticals (NASDAQ: INO) were up 20% early Thursday afternoon after the...
Big Pharma’s great lab monkey shortage: A crackdown on smuggling is causing chaos in America’s vital...
Fortune via Yahoo Finance· 3 months agoWhen Masphal Kry was taken into a back room for questioning at New York’s J.F.K. International...
27 Largest Biotech Companies in the US
Insider Monkey via Yahoo Finance· 12 months agoIn this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to...
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 months agoImage source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q4 2023 Earnings Call Mar 06,...
Vir to lay off staff, cut costs amid setbacks building on COVID success
BioPharma Dive via Yahoo Finance· 4 months agoDive Brief: Vir Biotechnology on Thursday announced a restructuring that will result in a 12%...
If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now
Zacks via Yahoo Finance· 2 years agoFor most investors, how much a stock's price changes over time is important. This factor can impact...
Why Novavax Stock Tumbled 28% in the First Half of 2023
Motley Fool· 9 months agoWhat happened Shares of Novavax (NASDAQ: NVAX) lost 28% of their value in the first six months of...
3 Biotech Stocks Outperforming a Bear Market
InvestorPlace via Yahoo Finance· 2 years ago2022 is likely to go down as one of the most challenging years for investors since 2008. Year-to-date, the S&P 500 is down more than 20%, while there is...
